Matching Luciferase Reporter Assays to Your Experimental Goals

Luciferase reporter assays are highly versatile, but their true power comes when the reporter system youโ€™ve selected is well aligned with your experimental objectives. Whether you’re tracking transcriptional changes or pathway activity, assessing miRNA/siRNA regulation, or using as a readout in CRISPR-based screens, choosing a reporter and detection assay format that fit your specific research goal is critical for meaningful, reproducible results.

You may have already read about how to choose a luciferase reporter assay, but now, we will walk through how to match luciferase reporter systemsโ€”reporter types, detection chemistries, and formatsโ€”to your specific experimental needs. While luciferases like NanoLuc have applications beyond gene expression, this blog focuses on genetic reporter applications and the workflows that support them.

Continue reading “Matching Luciferase Reporter Assays to Your Experimental Goals”

HiBiT-Based NanoBRETยฎ Assay Sheds Light on GPCRโ€“Ligand Binding in Live Cells

G-protein-coupled receptors (GPCRs) are among the most important drug targets in human biology, mediating signals across nearly every physiological system. But not all GPCRs are equally easy to studyโ€”especially those that interact with peptide ligands. These ligands tend to be flexible, fast-moving, and hard to trace in live cells by standard methods. Historically, radioligand binding assays have filled this gap, offering a way to measure peptideโ€“receptor interactions with high sensitivity. However, these assays are typically performed using isolated membrane preparations or cells under non-physiological conditions, and they donโ€™t allow for real-time or kinetic measurements.

Artistic Image of Hibit Tag

Continue reading “HiBiT-Based NanoBRETยฎ Assay Sheds Light on GPCRโ€“Ligand Binding in Live Cells”

How Computational Design Can Predict the Next Viral Variantโ€”and Help Us Prepare

As SARS-CoV-2 continues to evolve, one lesson is painfully clear: immunity today may not guarantee protection tomorrow. Viruses are experts at mutating into countless variants to evade detection or neutralization by the immune system. In the race to keep up with this “immune escape”, researchers have largely focused on reactive strategiesโ€”testing vaccines against variants that already exist. But what if we could flip the script and anticipate where the virus is going next?

Thatโ€™s precisely the aim of a new study published in Immunity.ย This study introducesย EVE-Vax, a computational design platform that builds synthetic spike proteins capable of mimicking immune escape mutationsโ€”before they naturally arise.

Continue reading “How Computational Design Can Predict the Next Viral Variantโ€”and Help Us Prepare”

20 Years of Organ Transplant Testing with Maxwellยฎ Instrumentation

MacKenzie Gartner, Lead Technologist at DCi, operates a Maxwellยฎ instrument.
MacKenzie Gartner, Lead Technologist at DCi, operates a Maxwellยฎ instrument.

For twenty years, the transplant lab at Dialysis Clinic, Inc. (DCi) in Nashville, TN has depended on Maxwell instruments for their automated nucleic acid purification. In fact, the lab was the first to purchase the instrument when it debuted in 2005. Today, theyโ€™ve scaled up to three of the latest Maxwellยฎ Instruments.

โ€œTheyโ€™re great little instruments,โ€ says Christina Sholar, Clinical Supervisor at DCi. โ€œI think this is our third generation, and we still have the original in the basement. We love them.โ€

Christinaโ€™s lab runs critical tests to ensure compatibility between donors and recipients for solid organ and stem cell transplants. With precious samples and urgent demands, they need tools they can depend on for high-quality results. Their Maxwellยฎ instruments help them ensure successful downstream analysis to support important clinical decisions.

Precious Samples, Urgent Timelines

A DCi lab technician adds a sample to a cartridge before loading the Maxwellยฎ instrument.
Hailey, a technician at DCi, loads a Maxwellยฎ cartridge.

Founded in 1971 as a non-profit dialysis clinic, DCi now supports a broad spectrum of kidney health issues, including transplants. The company has also expanded its operations to support organ transplants through federally designated organ procurement organizations. Christinaโ€™s lab runs the tests to ensure compatibility between donors and recipients.   

โ€œWe cover the state of Tennessee,โ€ Christina says. โ€œWe do the typing and antibody analysis for solid organ transplants, and then we follow them post-transplant to see if theyโ€™ve developed antibodies to the donor. We also do stem cell workups and follow-ups.โ€

The lab processes 150-200 samples per week. In addition to managing the high sample throughput, the team also must be available 24/7 for urgent calls when an organ donor passes away.

โ€œWe used to average about 50 donors a month, but thatโ€™s creeping up,โ€ Christina says.

Christina says her team needs a workflow built for speed and minimal hands-on processing. With downstream assays including NGS and qPCR, they also need to trust theyโ€™ll have a high-quality DNA sample to work with. Thatโ€™s what led them to the Maxwell platform in 2005.

Instrumentation for Easy, Reliable Results  

โ€œMaxwell purifications are an easy thing to start new employees with, because they can get quality DNA very easily,โ€ says MacKenzie Gartner, Lead Technologist in Christinaโ€™s lab at DCi. โ€œTechs pick up on it very quickly, and itโ€™s something they can feel confident in doing by themselves.โ€

Twenty years ago, the lab was using manual methods to purify all their nucleic acids. Unlike MacKenzie, Christina remembers those days and admits they werenโ€™t fun. The protocols were labor-intensive, and much more prone to human error. Now, they donโ€™t even teach manual methods anymore.

The DCi lab currently operates three Maxwellยฎ instruments.
The DCi lab currently operates three Maxwellยฎ instruments.

โ€œWhen I came on nine years ago, they were teaching a manual method as backup for the Maxwell instruments, but they never got around teaching it to me because it was needed so rarely,โ€ MacKenzie says. โ€œNow itโ€™s not even in the training materials.โ€

MacKenzie works hands-on with the Maxwell instruments almost every day. The lab mainly uses the Maxwellยฎ Buffy Coat DNA Kit and Maxwellยฎ Buccal Swab DNA Kit. Buccal swabs require 20 minutes of passive pre-processing, but buffy coats can be added directly to the Maxwell cartridges. From there, the automated protocol is only 45 minutes.

โ€œItโ€™s nice that both of them can be run on the same instrument, which gives us flexibility knowing that all three instruments can be available no matter what weโ€™re doing,โ€ MacKenzie adds.

One of the lab's original Maxwellยฎ instruments, still in storage in the basement.
One of the lab’s original Maxwellยฎ instruments, still in storage in the basement.

Christina says the Maxwell instruments provide much cleaner DNA eluates than their past manual methods. This is invaluable for lab efficiency, but itโ€™s even more important with stem cell testing.

โ€œWith stem cells, they may only send one tube but want three or four different tests,โ€ she explains. โ€œWe donโ€™t have room for error โ€“ those samples are precious.โ€

โ€œWe keep the instruments pretty active,โ€ MacKenzie adds. โ€œThat room constantly has their little noises going. But theyโ€™re so dependable โ€“ they donโ€™t take much maintenance, and we can count on having one available even when we get some urgent samples from a donor.โ€

Long-Term Partnership for Success

โ€œPromega is probably our favorite company to work with, as far as support goes,โ€ Christina says. โ€œWe rarely have issues, but when we do, we get great responses very quickly.โ€

As a leader, Christina values strong relationships with her suppliers. Though the labโ€™s sales representative has changed a few times over the past two decades, she says each one has been reliable and helpful in keeping the lab operations running smoothly. The lab has also benefited from regularly scheduled preventive maintenance visits from Promega service engineers.

โ€œOverall, I just love how dependable the instruments are,โ€ Christina says. โ€œWeโ€™re using them all the time. Theyโ€™re truly our workhorses.โ€

All photos credit: DCi


Targeting Epigenetic Regulators in Cancer: The Promise of BET and HDAC Inhibitors

This blog was written in collaboration with Tian Yang, Associate Product Manager at Promega.

Cancer is often driven not only by genetic mutations, but by changes in how genes are turned on or offโ€”epigenetic alterations. Two key players in this space are bromodomain and extra-terminal (BET) proteins and histone deacetylases (HDACs).

BET proteins help activate gene expression by recognizing acetylated lysines on histones, while HDACs remove these acetyl groups, repressing transcription. When these mechanisms become dysregulated, they can promote tumor growth or silence tumor suppressors.

To counteract this dysregulation, researchers have developed inhibitors that target BET proteins and HDACs. While combinations of these drugs have shown synergy, using two separate compounds introduces challenges with dosing, toxicity and pharmacokinetics. Recent efforts have focused on designing multitarget inhibitorsโ€”single molecules that can simultaneously block BET and HDAC activity.

Continue reading “Targeting Epigenetic Regulators in Cancer: The Promise of BET and HDAC Inhibitors”

5 Questions to Ask When Your RT-qPCR Isnโ€™t Working

RT-qPCR

RT-qPCR (reverse transcription quantitative PCR) is a powerful technique for quantifying RNA expressionโ€”but it doesnโ€™t always cooperate. Even when youโ€™ve followed the protocol carefully, unexpected results can appear: flat curves, unexpected Cq values, or inconsistent replicates. When that happens, youโ€™re left wondering… what went wrong?

In this blog, weโ€™ll walk through five key questions to help you troubleshoot RT-qPCR issues with confidence. From common errors to more stubborn challenges, weโ€™ll also explore what to consider when technique isnโ€™t fully the problemโ€”and when it might be time to rethink your reagents.

Continue reading “5 Questions to Ask When Your RT-qPCR Isnโ€™t Working”

Drug Target Confirmed? Tivantinibโ€™s Lesson on the Importance of Cellular Target Engagement

This guest blog post is written by Tian Yang, Associate Product Manager at Promega.

There are often challenges with translating results from a test tube into a living system, demanding more physiologically relevant assays. In drug discovery, demonstrating a compoundโ€™s ability to modulate its target protein in live cells is a critical step in the hit-to-lead workflow. A variety of cell-based assays can be used to assess a compoundโ€™s activity in live cells. Take kinase inhibitors as an example, these assays can range from substrate phosphorylation assays that more directly report on the activity of target kinases, to genetic reporter assays or cell viability assays that assess the downstream effects of target modulation.

In the case of Tivantinib, several pieces of data from its development were used to establish its role as an inhibitor of MET kinase. MET Kinase is a prominent target for anti-cancer therapeutics due to frequent MET dysregulation in a wide range of tumors. For example, over-activation of MET drives cancer proliferation and metastasis. In the initial report on Tivantinib, in addition to biochemical activity assays performed with purified MET, the activity of Tivantinib in cells was verified by several methods, including: 1) inhibition of phosphorylation of MET and downstream signaling pathways, 2) cytotoxicity in cancer cell lines expressing MET, and 3) antitumor activity in xenograft mouse models (1). Additionally, a co-crystal structure of the MET-Tivantinib complex was solved, seemingly confirming that Tivantinib is a bona fide MET inhibitor capable of engaging MET in live cells (2). Based on these observations and other pre-clinical data, Tivantinib appeared to be a promising drug candidate and was taken through phase 3 clinical trials targeting cancers with MET overexpression. However, Tivantinib ultimately was not approved as a new therapeutic, failing to show efficacy in these phase 3 clinical trials (3,4).  

Within three years of the initial publication on Tivantinib, two separate articles challenged the mechanism of action in Tivantinib-induced cytotoxicity of tumor cells (5,6). Authors for both articles showed that Tivantinib can kill both MET-addicted and nonaddicted cells with similar potency. Both articles also concluded that perturbation of microtubule dynamics, instead of MET inhibition, is likely responsible for the cytotoxicity observed with Tivantinib. Considering the failed clinical trials and uncertainties regarding the mechanism of action, one may wonder if the original pre-clinical work adequately determined if Tivantinib effectively binds and inhibits MET in cells? If Tivantinibโ€™s cellular engagement to MET was assessed directly rather than by MET phosphorylation analysis, would a different pre-clinical recommendation have been made?

Continue reading “Drug Target Confirmed? Tivantinibโ€™s Lesson on the Importance of Cellular Target Engagement”

Avoid the Summertime Blue-Greensโ€” Know about Cyanobacteria Before You Hit the Water

Warning sign reading "ALGAE BLOOM โ€“ NO SWIMMING" posted in a lake with visible green algae floating on the water's surface, surrounded by lily pads and aquatic plants under a clear blue sky.

The weather is warming up (at least in the Northern Hemisphere). There is nothing more refreshing on a hot summer day than a dip in cool lake waters, so people everywhere are digging out their swimsuits and hitting the beach. Unfortunately, the same warm temperatures that drive us to the beach can also cause a potentially deadly overgrowth of blue-green algae โ€”also called harmful algal blooms (HABs)โ€”in the water of our favorite pond or lake.

Continue reading “Avoid the Summertime Blue-Greensโ€” Know about Cyanobacteria Before You Hit the Water”

IL-6/STAT3-Regulated Long Non-Coding RNA Is Involved in Colorectal Cancer Progression

Researchers from Wenzhou Medical University in China have identified a mechanism involving long non-coding RNAs (lncRNA) that contributes to colorectal cancer (CRC) progression. CRC is the third most common cancer worldwide and is one of the most lethal cancers across the globe. Understanding the molecular mechanisms that underlie the development and progression of CRC is critical to developing biomarkers to detect it and new therapeutics to treat it.ย 

Continue reading “IL-6/STAT3-Regulated Long Non-Coding RNA Is Involved in Colorectal Cancer Progression”

Accurate and On-Time: A Look Inside Promega Logistics

Packages move through Kepler Center
Each week, thousands of parcels are shipped to customers from Kepler Center in Madison, WI.

Weโ€™re all used to the convenience of online ordering, whether itโ€™s a last-minute birthday gift or a phone charger delivered overnight. That same ease and speed is what scientists expect when ordering critical reagents for their work. At Promega, we get that. Thatโ€™s why we pledge: Youโ€™ll get what you need, when you need it.

For customers in the United States, any order received by 4:00 pm will be delivered the next day. We measure our success in honoring this pledge using a metric called โ€œorder fill rate.โ€ Our global order fill rate is consistently above our benchmark of 94.5%, sometimes passing 98%.

But how does that actually happen? With thousands of orders leaving our warehouse every week, it takes more than just good intentions. Here’s a look behind the scenes at how our teams deliver on that promise.

Continue reading “Accurate and On-Time: A Look Inside Promega Logistics”